Sanofi (SAN) Stock Forecast & Price Target

Compare

298 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAN Analyst Ratings

Moderate Buy

7 Buy

6 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAN Stock 12 Month Forecast

Average Price Target

€95.68

▲(23.11% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €95.68 with a high forecast of €118.50 and a low forecast of €84.64. The average price target represents a 23.11% change from the last price of €77.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"€79","89":"€89","99":"€99","109":"€109","119":"€119"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118.50102196859409,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€118.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.6828718004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€95.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.64358712042436,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€84.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,89,99,109,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.45,83.37700168989186,86.30400337978371,89.23100506967556,92.15800675956741,95.08500844945927,98.01201013935112,100.93901182924297,103.86601351913482,106.79301520902668,109.72001689891853,112.64701858881038,115.57402027870224,{"y":118.50102196859409,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.45,81.62175936926154,82.79351873852308,83.96527810778461,85.13703747704615,86.30879684630769,87.48055621556924,88.65231558483077,89.82407495409231,90.99583432335385,92.16759369261538,93.33935306187692,94.51111243113846,{"y":95.6828718004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.45,80.77258362464804,81.09516724929605,81.41775087394409,81.7403344985921,82.06291812324014,82.38550174788817,82.70808537253619,83.03066899718422,83.35325262183225,83.67583624648027,83.9984198711283,84.32100349577632,{"y":84.64358712042436,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.995,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.957,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.716,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.854,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.72,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€118.50

Average Price Target€95.68

Lowest Price Target€84.64

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Vosser

J.P. Morgan

€95

Hold

22.23%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)

Nicolas Pauillac

Kepler Capital

€85

Hold

9.37%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Karyopharm Therapeutics (NASDAQ: KPTI)

James Gordon CFA

Barclays

€85

Hold

9.37%

Upside

Reiterated

02/12/26

Sanofi (SNYNF) Receives a Hold from Barclays

James Quigley

Goldman Sachs

€90→€89

Hold

14.51%

Upside

Reiterated

01/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (NASDAQ: REGN), Resmed (NYSE: RMD) and Sanofi (Other OTC: SNYNF)

Matthew Weston

UBS

€88

Hold

13.23%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Sanofi (Other OTC: SNYNF) and Conmed (NYSE: CNMD)

Sachin Jain

Bank of America Securities

€102

Buy

31.24%

Upside

Reiterated

01/29/26

Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation

Benjamin Jackson CFA

Jefferies

€100

Buy

28.67%

Upside

Reiterated

01/29/26

Jefferies Sticks to Their Buy Rating for Sanofi (SNYNF)

Emmanuel Papadakis

Deutsche Bank

€105→€100

Buy

28.67%

Upside

Reiterated

01/27/26

Deutsche Bank Remains a Buy on Sanofi (SNYNF)

Graham Parry

Citi

€85

Hold

9.37%

Upside

Initiated

01/27/26

Sanofi initiated with a Neutral at CitiSanofi initiated with a Neutral at Citi

Luisa Hector

Berenberg Bank

€105

Buy

35.10%

Upside

Reiterated

01/20/26

Sanofi (SNYNF) Receives a Buy from Berenberg Bank

David Risinger

Leerink Partners

Buy

―

Reiterated

12/24/25

Analysts' Top Healthcare Picks: Sanofi (SNYNF), Genmab (GMAB)

Rajesh Kumar

HSBC

€102→€100

Buy

28.67%

Upside

Reiterated

12/10/25

Sanofi price target lowered to EUR 100 from EUR 102 at HSBCSanofi price target lowered to EUR 100 from EUR 102 at HSBC

Florent Cespedes

Bernstein

€119

Buy

53.11%

Upside

Reiterated

12/05/25

Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)

Elmar Kraus

DZ BANK AG

Buy

―

Reiterated

10/24/25

DZ BANK AG Sticks to Its Buy Rating for Sanofi (SNYNF)

Seamus Fernandez

Guggenheim

€104→€101

Buy

29.95%

Upside

Reiterated

10/08/25

Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Vosser

J.P. Morgan

€95

Hold

22.23%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (Other OTC: SNYNF) and Ocular Therapeutix (NASDAQ: OCUL)

Nicolas Pauillac

Kepler Capital

€85

Hold

9.37%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Karyopharm Therapeutics (NASDAQ: KPTI)

James Gordon CFA

Barclays

€85

Hold

9.37%

Upside

Reiterated

02/12/26

Sanofi (SNYNF) Receives a Hold from Barclays

James Quigley

Goldman Sachs

€90→€89

Hold

14.51%

Upside

Reiterated

01/30/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (NASDAQ: REGN), Resmed (NYSE: RMD) and Sanofi (Other OTC: SNYNF)

Matthew Weston

UBS

€88

Hold

13.23%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX), Sanofi (Other OTC: SNYNF) and Conmed (NYSE: CNMD)

Sachin Jain

Bank of America Securities

€102

Buy

31.24%

Upside

Reiterated

01/29/26

Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation

Benjamin Jackson CFA

Jefferies

€100

Buy

28.67%

Upside

Reiterated

01/29/26

Jefferies Sticks to Their Buy Rating for Sanofi (SNYNF)

Emmanuel Papadakis

Deutsche Bank

€105→€100

Buy

28.67%

Upside

Reiterated

01/27/26

Deutsche Bank Remains a Buy on Sanofi (SNYNF)

Graham Parry

Citi

€85

Hold

9.37%

Upside

Initiated

01/27/26

Sanofi initiated with a Neutral at CitiSanofi initiated with a Neutral at Citi

Luisa Hector

Berenberg Bank

€105

Buy

35.10%

Upside

Reiterated

01/20/26

Sanofi (SNYNF) Receives a Buy from Berenberg Bank

David Risinger

Leerink Partners

Buy

―

Reiterated

12/24/25

Analysts' Top Healthcare Picks: Sanofi (SNYNF), Genmab (GMAB)

Rajesh Kumar

HSBC

€102→€100

Buy

28.67%

Upside

Reiterated

12/10/25

Sanofi price target lowered to EUR 100 from EUR 102 at HSBCSanofi price target lowered to EUR 100 from EUR 102 at HSBC

Florent Cespedes

Bernstein

€119

Buy

53.11%

Upside

Reiterated

12/05/25

Bernstein Sticks to Its Buy Rating for Sanofi (SNYNF)

Elmar Kraus

DZ BANK AG

Buy

―

Reiterated

10/24/25

DZ BANK AG Sticks to Its Buy Rating for Sanofi (SNYNF)

Seamus Fernandez

Guggenheim

€104→€101

Buy

29.95%

Upside

Reiterated

10/08/25

Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

3 Months

xxx

Success Rate

19/35 ratings generated profit

Average Return

-0.01%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.29% of your transactions generating a profit, with an average return of -0.01% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

21/35 ratings generated profit

Average Return

+3.55%

reiterated a buy rating 2 months ago

Copying David Risinger's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +3.55% per trade.

2 Years

xxx

Success Rate

15/26 ratings generated profit

Average Return

+6.49%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.69% of your transactions generating a profit, with an average return of +6.49% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAN Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAN has received 21 Buy Ratings, 29 Hold Ratings, and 0 Sell Ratings. SAN average Analyst price target in the past 3 months is 95.68.

Each month's total comprises the sum of three months' worth of ratings.

SAN Financial Forecast

SAN Earnings Forecast

Next quarter’s earnings estimate for SAN is €1.78 with a range of €1.59 to €1.87. The previous quarter’s EPS was €1.53. SAN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SAN has Performed in-line its overall industry.

SAN Sales Forecast

Next quarter’s sales forecast for SAN is €10.50B with a range of €9.88B to €10.85B. The previous quarter’s sales results were €23.74B. SAN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SAN has Performed in-line its overall industry.

SAN Stock Forecast FAQ

What is FR:SAN’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 95.68.

What is FR:SAN’s upside potential, based on the analysts’ average price target?

Sanofi has 23.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sanofi a Buy, Sell or Hold?

Sanofi has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 6 hold ratings and 0 sell ratings.

What is Sanofi’s share price target?

The average share price target for Sanofi is 95.68. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €118.50 ,and the lowest forecast is €84.64. The average share price target represents 23.11% Increase from the current price of €77.72.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Sanofi?

To buy shares of FR:SAN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sanofi (SAN) Stock Forecast & Price Target

SAN Analyst Ratings

SAN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SAN Analyst Recommendation Trends

SAN Financial Forecast

SAN Earnings Forecast

SAN Sales Forecast

SAN Stock Forecast FAQ

Detailed List of Analyst Forecasts